BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 1,484 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 1,484 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $269.37, for a total value of $399,745.08. Following the completion of the sale, the chief operating officer directly owned 40 shares in the company, valued at $10,774.80. This trade represents a 97.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

BeOne Medicines stock traded down $4.56 during trading hours on Wednesday, hitting $263.61. The stock had a trading volume of 291,079 shares, compared to its average volume of 255,249. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The stock has a market capitalization of $28.92 billion, a price-to-earnings ratio of 58.97 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The stock’s fifty day moving average is $301.03 and its two-hundred day moving average is $315.60.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of large investors have recently made changes to their positions in ONC. Cetera Investment Advisers acquired a new stake in shares of BeOne Medicines during the second quarter valued at $455,000. Rhumbline Advisers purchased a new position in BeOne Medicines during the second quarter worth about $275,000. Arrowstreet Capital Limited Partnership purchased a new position in BeOne Medicines during the second quarter worth about $505,000. Invesco Ltd. purchased a new position in BeOne Medicines during the second quarter worth about $422,000. Finally, EverSource Wealth Advisors LLC purchased a new position in BeOne Medicines during the second quarter worth about $68,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Morgan Stanley reissued an “overweight” rating and issued a $395.00 target price on shares of BeOne Medicines in a report on Thursday, May 7th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Barclays increased their price objective on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, Wells Fargo & Company started coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.